



Docket Number No. 91.US4.DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Applicant : BEJANIN, et al.

Appl. No. : 09/992,600

Filed : November 13, 2001

Title : HUMAN CDNAS AND PROTEINS AND USES
THEREOF

Grp./A.U. : 15
Examiner : [Signature]

RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

Honorable Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits the references listed on the attached forms PTO/SB/08A and 08B, copies of which are enclosed. This statement is being filed before the receipt of a first Office Action on the merits.

The Commissioner is hereby authorized to charge any fees in connection with this document to our Deposit Account No.: 50-1181

Respectfully submitted,

GENSET CORPORATION

Date: 4/15, 2002

By:

[Signature]
John Lucas, Ph.D., J.D.

Registration No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (858) 597-2600

Facsimile: (858) 597-2601

e-mail: john.lucas@genxy.com

Certificate of Mailing under 37 CFR 1.10


Date of Deposit: 4-25-02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

[Signature]
Signature

Deno P. Dialynas

Typed or Printed Name of Person Signing Certificate



RECEIVED

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 21 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/992.600
		Filing Date	November 13, 2001
		First Named Inventor	BEJANIN, et al.
		Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	91.US4.DIV
Sheet	1	of	4

U.S. PATENT DOCUMENTS					
Examiner Initials ⁷	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁷	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
	A		WO 01/53455 - A2	07/26-2001	Hvseq. Inc.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JUN 21 2002

PTO/SB/08B (10-01)
Approved for use, product 07/2004, 08/2007, 03/2011
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/992,600
		Filing Date	November 13, 2001
		First Named Inventor	BEJANIN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	91.US4.DIV
Sheet	2 of 4		


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B	KIM, S., et al.; "Regulation of Plasminogen Receptor Expression on Monocytoid Cells by B1-Integrin-dependent Cellular Adherence to Extracellular Matrix Proteins"; The Journal of Biological Chemistry; Vol. 271, No. 39, Issue of September 27, pp. 23761-23767, 1996; The American Society for Biochemistry & Molecular Biology, Inc.	
	C	MAO, S., et al.; "Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B"; The Journal of Biological Chemistry, Vol. 274, No. 49, Issue of December 3, pp. 35046-35052, 1999; The American Society for Biochemistry and Molecular Biology, Inc.	
	D	REMINGTON, James S.; "Serine carboxypeptidases: a new and versatile family of enzymes"; Current Opinion in Biotechnology 1993, 4:462-468; Current Biology Ltd.; ISSN 0958-1669	
	E	FRUEBIS, J., et al.; "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice"; PNAS, February 13, 2001, Vol. 98, No. 4; 2005-2010	
	F	HAMSTRA, D.A., et al.; "Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate- α -peptide prodrugs"; Cancer Research 50, 657-665, February 1, 2000	
	G	MATSUMOTO, A., et al.; "A novel carboxypeptidase B that processes native B-amyloid precursor protein is present in human hippocampus"; European Journal of Neuroscience, Vol. 12, pp. 227-238, 2000; European Neuroscience Association	
	H	HERREN, T., et al.; "Regulation of plasminogen binding to neutrophils"; Blood, 15 February 2001, Vol. 97, No. 4, pp. 1070-1078; The American Society of Hematology	
	I	DU, J., et al.; "Key peptide processing enzymes are expressed by breast cancer cells"; Cancer Letters 165 (2001) 2111-218; 0304-3835/00; Elsevier Science Ireland Ltd.	
	J	NAPIER, M.P., et al.; "Antibody-directed Enzyme Prodrug Therapy: Efficacy and Mechanism of Action in Colorectal Carcinoma"; Clinical Cancer Research, Vol. 6, 765-772, March 2000	
	K	SHI, P.T., et al.; "The solid-phase synthesis of methotrexate- α -peptides"; Yao Xue Xue Bao, 1997; 32(2):106-9; Abstract, PMID: 11243192 [PubMed - indexed for MEDLINE]	
	L	Accession No. Q96A94; STRAUSBERG, R.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/992.600
Sheet	3	Filing Date	November 13, 2001
	of	First Named Inventor	BEJANIN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	91.US4.DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	M	Accession No. Q9HB40; CHO, et al.; "Cloning of novel serine carboxypeptidase precursor"	
	N	Accession No. AAM25395; TANG, et al.; "Isolated human polynucleotides encoding polypeptides, useful for the treatment and diagnosis of e.g. cancer, ulcers and HIV infection"	
	O	Celera Protein Accession No. hCP1766200	
	P	Celera Protein Accession No. hCP46705.2	
	Q	Celera Protein Accession No. hCP1766203	
	R	Accession No. AAY05768; FONG, et al.; "Composition containing human polypeptides with anti-angiogenic activity"	
	S	Accession No. AAY13387; CHEN, et al.; "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration"	
	T	Accession No. AAY88378; FONG, et al.; "A composition comprising PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals"	
	U	Accession No. AAE06595; KATO, et al.; "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"	
	V	Accession No. AAB93913; OTA, et al.; "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs"	
	W	Accession No. AAB20341; Fong, et al.; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist from promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals"	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JUN 21 2002
TECH CENTER 1600/2900



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/992.600		
		Filing Date	November 13, 2001		
		First Named Inventor	BEJANIN, et al.		
		Group Art Unit	1645		
		Examiner Name	Unassigned		
Sheet	4	of	4	Attorney Docket Number	91.US4.DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	X	Accession No. AAB80255; ASHKENAZI, et al.; "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's disease)"	
	Y	Accession No. CAC51169; KATO, et al.; "Human proteins having hydrophobic domains and dnas encoding these proteins"	
	Z	Accession No. AF282618; CHO, et al.; "Cloning of novel serine carboxypeptidase precursor"	
	AA	Accession No. AK027373; ISOGAI, et al.; "NEDO human cDNA sequencing project"	
	AB	Accession No. AX191563; KATO, et al.; "Human proteins having hydrophobic domains and dnas encoding these proteins"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JUN 21 2002